嵌合抗原受体T细胞治疗血液肿瘤的发展与应用

张曦; 黄瑞昊

doi:10.16016/j.1000-5404.201907013

您当前的位置：

首页 >

文章列表页 >

嵌合抗原受体T细胞治疗血液肿瘤的发展与应用

专题报道：造血干细胞移植与细胞治疗 | 更新时间：2026-01-09

- 嵌合抗原受体T细胞治疗血液肿瘤的发展与应用
- Clinical application of CAR-T cells in treatment of hematologic malignancies
- 第三军医大学学报 2019年41卷第23期页码：2261-2266
- 作者机构：
- 作者简介：
- 基金信息：
  
  重庆市社会事业与民生保障科技创新专项(CSTC2016shms-ztzx10003);校临床重大领域技术创新项目(CX2019LC111);院级临床重大创新特色技术项目军民融合专项(2018JSLC0020)
- DOI：10.16016/j.1000-5404.201907013
  中图分类号：
- 收稿：2019-07-02，
  
  纸质出版：2019-12-25
- 稿件说明：
移动端阅览
张曦, 黄瑞昊. 嵌合抗原受体T细胞治疗血液肿瘤的发展与应用[J]. 第三军医大学学报, 2019,41(23):2261-2266.

Xi ZHANG, Ruihao HUANG. Clinical application of CAR-T cells in treatment of hematologic malignancies[J]. Journal of Third Military Medical University, 2019, 41(23): 2261-2266.
张曦, 黄瑞昊. 嵌合抗原受体T细胞治疗血液肿瘤的发展与应用[J]. 第三军医大学学报, 2019,41(23):2261-2266. DOI： 10.16016/j.1000-5404.201907013.

Xi ZHANG, Ruihao HUANG. Clinical application of CAR-T cells in treatment of hematologic malignancies[J]. Journal of Third Military Medical University, 2019, 41(23): 2261-2266. DOI： 10.16016/j.1000-5404.201907013.

摘要

Abstract

The stunning benefits of chimeric antigen receptor T (CAR-T) cell therapy in treatment of relapsed and/or refractory (R/R) B cell acute lymphoblastic leukemia have brought hope to the patients with R/R hematologic malignancies. With the aims of achieving more effective and more accessible CAR-T cell therapy

large-scale hospitals all over the world have launched clinical trails by adjusting the CAR structure

complementary treatment and management of side-effects. Great progresses had been made in the CAR structure optimization

efficiency and safety of clinical application

and transformation and survival of CAR-T cells. The process of clinical application of CAR-T cell therapy is gradually clear

and the effective measures for complications are gradually enriched. However

there still are some disappointing outcomes from clinical trails aimed at acute myeloblastic leukemia (AML)

which are the challenges badly in need of solutions. In order to finally grasp the success or failure

we must analyze the causes in multiple aspects

from preparation to clinical application

and continuously improve and optimize. In this paper

we sorted out the development trend of CAR-T cell therapy and problems needing be urgently solved in the treatment of hematological malignancies in recent years

and made the prospect for the future.

关键词

Keywords

references

GROSS G WAKS T ESHHAR Z Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 1989 86 24 10024 10028 10.1073/pnas.86.24.10024 GROSS G, WAKS T, ESHHAR Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989, 86(24): 10024-10028. DOI:10.1073/pnas.86.24.10024.

KAWALEKAR O U O'CONNOR R S FRAIETTA J A Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells Immunity 2016 44 2 380 390 10.1016/j.immuni.2016.01.021 KAWALEKAR O U, O'CONNOR R S, FRAIETTA J A, et al . Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells[J ] . Immunity, 2016, 44(2): 380-390. DOI:10.1016/j.immuni.2016.01.021.

LONG A H HASO W M SHERN J F 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors Nat Med 2015 21 6 581 590 10.1038/nm.3838 LONG A H, HASO W M, SHERN J F, et al . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J ] . Nat Med, 2015, 21(6): 581-590. DOI:10.1038/nm.3838.

RAMOS C A ROUCE R ROBERTSON C S In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas Mol Ther 2018 26 12 2727 2737 10.1016/j.ymthe.2018.09.009 RAMOS C A, ROUCE R, ROBERTSON C S, et al . In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas[J ] . Mol Ther, 2018, 26(12): 2727-2737. DOI:10.1016/j.ymthe.2018.09.009.

ENBLAD G KARLSSON H GAMMELGÅRD G A phase Ⅰ/Ⅱa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia Clin Cancer Res 2018 24 24 6185 6194 10.1158/1078-0432.CCR-18-0426 ENBLAD G, KARLSSON H, GAMMELGÅRD G, et al . A phase Ⅰ/Ⅱa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia[J ] . Clin Cancer Res, 2018, 24(24): 6185-6194. DOI:10.1158/1078-0432.CCR-18-0426.

GUEDAN S POSEY A D Jr SHAW C Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation JCI Insight 2018 3 1 96976 10.1172/jci.insight.96976 GUEDAN S, POSEY A D Jr, SHAW C, et al . Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation[J ] . JCI Insight, 2018, 3(1): 96976. DOI:10.1172/jci.insight.96976.

ZHANG X LU X YANG J Efficacy and safety of CD19 chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphocytic leukemia (B-cell aLL) in a large cohort including patients with extramedullary disease(EMD), high leukemia burden, BCR-ABL (+) mutation, TP53 mutation, and post-transplant relapse Blood 2018 132 Suppl 1 280 10.1182/blood-2018-99-115642 ZHANG X, LU X, YANG J, et al . Efficacy and safety of CD19 chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphocytic leukemia (B-cell aLL) in a large cohort including patients with extramedullary disease(EMD), high leukemia burden, BCR-ABL (+) mutation, TP53 mutation, and post-transplant relapse[J ] . Blood, 2018, 132(Suppl 1):280. DOI:10.1182/blood-2018-99-115642.

LIU J ZHONG J F ZHANG X Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies J Hematol Oncol 2017 10 1 35 10.1186/s13045-017-0405-3 LIU J, ZHONG J F, ZHANG X, et al . Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B c ell malignancies[J ] . J Hematol Oncol, 2017, 10(1): 35. DOI:10.1186/s13045-017-0405-3.

HOFMANN S SCHUBERT M L WANG L Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML) J Clin Med 2019 8 2 E200 10.3390/jcm8020200 HOFMANN S, SCHUBERT M L, WANG L, et al . Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML)[J ] . J Clin Med, 2019, 8(2): E200. DOI:10.3390/jcm8020200.

HIRAYAMA A V GAUTHIER J HAY K A The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells Blood 2019 133 17 1876 1887 10.1182/blood-2018-11-887067 HIRAYAMA A V, GAUTHIER J, HAY K A, et al . The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells[J ] . Blood, 2019, 133(17): 1876-1887. DOI:10.1182/blood-2018-11-887067.

HAY K A Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy Br J Haematol 2018 183 3 364 374 10.1111/bjh.15644 HAY K A. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy[J]. Br J Haematol, 2018, 183(3): 364-374. DOI:10.1111/bjh.15644.

ANAND K BURNS E SANO D Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS J Clin Oncol 2019 37 15_suppl 2540 10.1200/jco.2019.37.15_suppl.2540 ANAND K, BURNS E, SANO D, et al . Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS[J ] . J Clin Oncol, 2019, 37(15_suppl): 2540. DOI:10.1200/jco.2019.37.15_suppl.2540.

CHEN F TEACHEY D T PEQUIGNOT E Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy J Immunol Methods 2016 434 1 8 10.1016/j.jim.2016.03.005 CHEN F, TEACHEY D T, PEQUIGNOT E, et al . Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy[J ] . J Immunol Methods, 2016, 434: 1-8. DOI:10.1016/j.jim.2016.03.005.

STERNER R M SAKEMURA R COX M J GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts Blood 2019 133 7 697 709 10.1182/blood-2018-10-881722 STERNER R M, SAKEMURA R, COX M J, et al . GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J ] . Blood, 2019, 133(7): 697-709. DOI:10.1182/blood-2018-10-881722.

KADAUKE S MAUDE S GLADNEY W Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019) Cytotherapy 2019 21 5 e2 e3 10.1016/j.jcyt.2019.04.009 KADAUKE S, MAUDE S, GLADNEY W, et al . Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)[J ] . Cytotherapy, 2019, 21(5): e2-e3. DOI:10.1016/j.jcyt.2019.04.009.

NORELLI M CAMISA B BARBIERA G Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells Nat Med 2018 24 6 739 748 10.1038/s41591-018-0036-4 NORELLI M, CAMISA B, BARBIERA G, et al . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J ] . Nat Med, 2018, 24(6): 739-748. DOI:10.1038/s41591-018-0036-4.

PARK J H RIVIÈRE I GONEN M Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia New Engl J Med 2018 378 5 449 459 10.1056/NEJMoa1709919 PARK J H, RIVIÈRE I, GONEN M, et al . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J ] . New Engl J Med, 2018, 378(5):449-459. DOI:10.1056/NEJMoa1709919.

HAMIEH M DOBRIN A CABRIOLU A CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape Nature 2019 568 7750 112 116 10.1038/s41586-019-1054-1 HAMIEH M, DOBRIN A, CABRIOLU A, et al . CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape[J ] . Nature, 2019, 568(7750): 112-116. DOI:10.1038/s41586-019-1054-1.

LIN J K MUFFLY L S SPINNER M A Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma J Clin Oncol 2019 37 24 2105 2119 10.1200/JCO.18.02079 LIN J K, MUFFLY L S, SPINNER M A, et al . Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma[J ] . J Clin Oncol, 2019, 37(24): 2105-2119. DOI:10.1200/JCO.18.02079.

MESTERMANN K GIAVRIDIS T WEBER J The tyrosine kinase inhibitor dasatinib Acts as a pharmacologic on/off switch for CAR T cells Sci Transl Med 2019 11 499 eaau5907 10.1126/scitranslmed.aau5907 MESTERMANN K, GIAVRIDIS T, WEBER J, et al . The tyrosine kinase inhibitor dasatinib Acts as a pharmacologic on/off switch for CAR T cells[J ] . Sci Transl Med, 2019, 11(499): eaau5907. DOI:10.1126/scitranslmed.aau5907.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

多发性骨髓瘤患者基于铜死亡相关基因预后模型的构建与验证

新药时代下如何为异基因造血干细胞移植赋能

靶向抑制DNAJC1基因对多发性骨髓瘤细胞凋亡和增殖的影响

内科胸腔镜对淋巴瘤所致胸腔积液的诊断价值